Modality For Disseminated Intravascular Coagulation And Current Treatment

Disseminated Intravascular Coagulation (DIC) is a systemic syndrome that causes thrombosis in small and mediumdiameter vessels as a result of disruption of hemostatic balance by several reasons, and progresses with the consumption of thrombocyte and coagulation factors, severe hemorrhage and impaired organ perfusion as a result of ac tivation of disseminated intravascular coagulation mechanism. DIC is always a complication that occurs together with some diseases and various secondary pathological conditions. The tissue factor which occurs as a result of tissue factor firstly activates the coagulation cascade; and overproduction of thrombin forms the basis of pathogenesis of DIC. The clinical course of DIC is generally under the influence of the underlying etiologic factor. There is not a laboratory test diagnosing DIC alone; however, the laboratory findings are indispensable for diagnosis. Treating the disease causing DIC and predominant signs of bleeding or thrombosis in clinical table, and conducting prophylaxis for preventing repetitions in chronic DIC cases are the main steps of treatment.

___

1. Wada H, Thachil J, Di Nisio M, et al. The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis. Guidance for diagnosis andtreatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines. Journal of Thrombosis and Haemostasis 2013; 11: 761-767.

2. Levi Marcel, Tom van der Poll. A short contemporary history of disseminated intravascular coagulation. Seminars in Thrombosis and Hemostasis 2014; 40: 874- 880.

3. Saba HI, Morelli GA. The pathogenesis and management of disseminated intravascular coagulation. Clin Adv Hemato Onco 2006; 4: 919-926.

4. Levi M. Disseminated intravascular coagulation: what’s new? Crit Care Clin 2005; 21: 449-467.

5. Bick RL. Disseminated intravascular coagulation: a review of etiology, pathophysiology, diagnosis, and management: guidelines for care. Clin Appl Thromb Hemost 2002; 8: 1-31.

6. Monagle P, Andrew M. Acquired disorders of hemostasis. In: Nathan DG, Orkin SH, Ginsburg D, Look AT (eds), Nathan and Oski’s hematology of Infancy and Childhood (6thed) Saunders, Philadelphia 2003; 1633- 1635.

7. Bick RL. Disseminated intravascular coagulation current concepts of etiology, pathophysiology, diagnosis, and treatment. Hematol Oncol Clin North Am 2003; 17: 149- 176.

8. Kitchens CS. Disseminated intravascular coagulation. In: Kitchens CS, Alving BM, Kessler CM (eds). Consultative hemostasis and thrombosis. First edition WB. Saunders company, Philadelphia 2002; 165-1783.

9. Osterud B, Bjorklid E. The tissue factor pathway in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27: 605-617.

10. De Jonge E, van der Poll T, Kesecioglu J, Levi M. Anticoagulant factor concentrates in disseminated intravascular coagulation: rationale for use and clinical experience. Semin Thromb Hemost 2001; 27: 667-674.

11. Kessler CM, Tang Z, Jacobs HM, Szymanski LM. The suprapharmacological dosing of antitrombin concentrate for staphylococcus aureus–induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood 1997; 89: 4393-4401.

12. Mesters RM, Mannuchi PM, Coppola R, Keller T, Osterman H, Kienast J. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996; 88: 881-886.

13. Wada H, et al. Disseminated intravascular coagulation: Testing and diagnosis. Clinica Chimica Acta 2014; 130-134.

14. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Journal of Haematology 2009; 145: 24- 33.

15. Levi M. Diagnosis and treatment of disseminated intravascular coagulation. International Journal of Laboratory Hematology 2014; 36: 228-236.

16. Gando S, Yasuhiro O. Local hemostasis, immunothrombosis,and systemic disseminated intravascular coagulation in trauma and traumatic shock. Endothelium 2015; 2: 2-11.

17. Levi M, ten Ctae H. Disseminated intravascular coagulation. N Engl J Med 2001; 345: 408-416.

18. West AP, Shadel GS. Mitochondrial DNA in Innate Immune Responses andInflammatory Pathology. Nat Rev Immunol 2017; 17: 363- 375.

19. Jiang WW Increased Mitochondrial DNA Content in Saliva Associated with Head and Neck Cancer. Clinical Cancer Research 2005; 11: 2486-2491.

20. Ho PWL, Pang WF, Luk CCW, et al Urinary Mitochondrial DNA Level as a Biomarker of Acute Kidney Injury Severity. Kidney Diseases 2017; 3: 78-83.

21. Hajizadeh S, DeGroot J, TeKoppele JM, Tarkowski A, Collins LV. Extracellular Mitochondrial DNA and Oxidatively Damaged DNA in Synovial Fluid of Patients with Rheumatoid Arthritis. Arthritis Research & Therapy 2003; 5: 234-240.

22. Pyle A, Anugrha H, Kurzawa-Akanbi M, Yarnall A, Burn D, Hudson G. Reduced Mitochondrial DNA Copy Number is a Biomarker of Parkinson’s Disease. Neurobiol Aging 2016; 38: 216.e7-216.e10.

23. West AP, Shadel GS, Ghosh S. Mitochondria in Innate Immune Responses. Nat Rev Immunol 2011; 11: 389-492.

24. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010; 464: 104- 107.

25. Lichtenstein AV, Melkonyan HS, Tomeı LD, Umansky SR. Circulating Nucleic Acids and Apoptosis. Annals of the New York Academy of Sciences 2006; 945: 239-249.

26. Picca A, Lezza AMS, Leeuwenburgh C, et al. Fueling Inflamm-Aging Through Mitochondrial Dysfunction: Mechanisms and Molecular Targets. Int J Mol Sci 2017; 18:pii:E933.

27. Weinberg SE, Sena LA, Chandel NS. Mitochondria in Regulation of Innate and Adaptive Immunity. Immunity 2015; 17: 406- 417.

28. Chiu RW, Chan LY, Lam NY, et al. Quantitative Analysis of Circulating Mitochondrial DNA in Plasma. Clin Chem 2003; 49: 719-726.

29. Nakahira K, Hisata S, Choi AMK. The Roles of Mitochondrial Damage-Associated Molecular Patterns in Diseases. Antioxid Redox Signal 2015; 23: 1329-1350.

30. Kelly AL. Disseminated intravascular coagulation; pathophysiology, manifestations and managament in the emergency department. AENJ 1998; 1: 24-28.

31. Montgomery RR, Scot JP. Hemorrhagic and thrombotic diseases. Behrman RE, Kliegman RM, Jenson HB. (Eds). Nelson Textbook of Pediatrics (17th edition). Philedelphia: Saunders 2004; 1651-7164.

32. Ho LWW, Kam PCA, Thong CL. Disseminated intravascular coagulation. Current Anaesthesia & Critical Care 2005; 16: 151-161.

33. Faust SN. Disseminated intravascular coagulation and purpura fulminans secondary to infection. Bailliere's Clinical Haematology 2000; 13: 179-197.

34. Wada H, Matsumoto T, Hatada T. Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. Expert Rev Hematol 2012; 5: 643-652.

35. Septic Shock. In: Salyers AA, Whitt DD (eds). Bacterial Pathogenesis: A Molecular Approach. ASM Press, Washington DC 1994; 56-60.

36. Fourrier F1, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, Protein C and Protein S deficiencies. Chest 1992; 101: 816-823.

37. Wada H, Wakita Y, Nakase T, et al. Increased plasma-soluble fibrin monomer levels in patients with disseminated intravscular coagulation. Am J Hematol 1996; 51: 255-260.

38. Taylor FB, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation–on behalf of the Scientific Subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Thromb Haemost 2001; 86: 1327-1330.

39. Stainsby D, MacLennon S, Hamilton PJ. Management of massive blood loss: a template guideline. Br J Anaest 2000; 85: 487-491.

40. Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999; 340: 409-417.

41. Franchini M, Lippi G, Manzato F. Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation. Thrombosis Journal 2006, 4: 1-9.

42. Levi M, Levy M, Williams MD, et al. Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 2007; 176: 483- 490.

43. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing therapeutic range for heparin therapy. Ann Intern Med 1993; 119: 104-109.

44. Elg M, Gustafsson D. A combination of a thrombin inhibitor and dexamethasone prevents the development of experimental disseminated intravascular coagulation in rats. Thrombosis Research 2006; 117: 429-437.

45. Vlasuk G, Bergum P, Bradbury A, Loynds P, Mant T, Rote W. Clinical evaluation of rNAPc2, an inhibitor of the fVIIa/tissue factor coagulation complex. A J Cardiol 1997; 80: 66.

46. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo controlled, single-blind, dose escalation study. Crit Care Med 2001; 29: 2081-2089.

47. Moons AH, Peters RJ, Cate Ht, et al. Recombinant nematode anticoagulan protein c2, a novel inhibitör of tissue factor-factor VIIa activity, abrogates endotoxin induced coagulation in chimpanzees. Thromb Haemost 2002; 88: 627-631.

48. Giudici D, Baudo F, Palareti G, Ravizza A, Ridolfi L, D' Angelo A. Antitrombin replacement in patients with sepsis and septic shock. Haematologica 1999; 84: 452-460.

49. Warren BL, Eid A, Singer P, et al. KyberSept Trial Study Group.High dose antitrombin III in severe sepsis. JAMA 2001; 286: 1869-1878.

50. Bernard GR, Ely EW, Wright TJ, et al.. Safety and dose relationship of recombinant human activated protein C for severe sepsis. Crit Care Med 2001; 29: 2051-2059.

51. Bernard GR, Vincent JL, Laterre PF, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for sepsis. N Eng J Med 2001; 334: 699-709.

52. Dhainaut JF, Laterre PF, Janes JM, et al. Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple organ dysfunction: Data from the PROWESS trial. Intensive Care Med 2003; 29: 894-903.

53. Laterre PF. Clinical trials in sepsis with drotrecegin alfa (activated). Crit Care 2007; 11 Suppl 5: S5.

54. Sarangi PP, Lee HW, Kim M. Activation Protein C action in inflammation. Br J Haematol 2010; 148: 817-833.

55. Gralnick HR, Greipp P. Thrombosis with epsilon aminocaproic acıd therapy. Am J Clin Pathol 1971; 56: 151-154.

56. Manucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356: 2301-2311.

57. Moscardó F, Pérez F, de la Rubia J, et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. British Journal of Haematology 2001; 113: 174-176.
Eastern Journal of Medicine-Cover
  • ISSN: 1301-0883
  • Başlangıç: 1996
  • Yayıncı: ERBİL KARAMAN
Sayıdaki Diğer Makaleler

Tuberculosis Cases in Mardin Between 2012 And 2018

Mehmet KABAK, Barış ÇİL, İCLAL HOCANLI, CENGİZHAN SEZGİ, MAHŞUK TAYLAN, Ufuk DÜZENLİ

Modality For Disseminated Intravascular Coagulation And Current Treatment

Yaren DİRİK, Pınar KOLUSARI

Evaluation and Comparison of Patients Poisoned with Acetaminophen and Nonsteroidal Anti-Inflammatory Drugs

Ahmet ÇELİK, MUHAMMED İKBAL ŞAŞMAZ

Attitudes of Anesthesiology and Reanimation Specialists Towards Pediatric Anesthesia Outside of the Operating Room Practices: A Survey Analysis

CELALEDDİN SOYALP, NUREDDİN YÜZKAT

Retrospective Analysis of Pesticide Poisoning in Rural Area

DERYA ADIBELLİ, İlknur ÖZKAN, Hasan Ömür ÖZKAN

Prick Test Results and Total IgE Levels of Asthma Patients in A University Hospital

Barış ÇİL, Mehmet KABAK, İCLAL HOCANLI, Ayşe Füsun TOPÇU, MAHŞUK TAYLAN

A Successful Intra-Pleural Fibrinolytic Therapy With Alteplase in A Patient with Empyematous Multiloculated Chylothorax

Mohamed FAİSAL, Rayhan AMİSENO, Nurashikin MOHAMMAD

The Comparison of Diffusion Weighted Imaging (DWI) with Other Breast MRI Parameters in the diagnosis of Breast Masses

Mesut OZGOKCE, Nuri HAVAN, Ferhat CUCE, Fatma DURMAZ, Zakir SAKCI

Expression Profiles of TRAIL and Its Receptors in Normal, Hyperplastic, and Malignant Endometrial Tissues: Hints on Endometrial Cancer Biology

ÇİĞDEM AYDIN ACAR, ATIL BİŞGİN, AHTER DİLŞAD ŞANLIOĞLU, HADİCE ELİF PEŞTERELİ, GÜLGÜN ERDOĞAN, İREM HİCRAN ÖZBUDAK, Tayup ŞİMŞEK, Salih ŞANLIOĞLU

Anesthesia Management in Laparoscopic Sleeve Gastrectomy Cases

ARZU ESEN TEKELİ, Esra EKER, Mehmet Kadir BARTIN, Muzaffer Önder ÖNER